Thymosin Alpha 1

What it is

The thymus gland, an organ behind the breastbone that trains immune cells early in life, naturally produces a hormone called thymosin alpha 1. The lab-made version used in research and medicine is built to match that natural hormone's exact sequence of 28 amino acids, rather than being a modified or partial copy of it.

In the research literature, thymosin alpha 1 is described as engaging several different immune-signaling pathways at once, a pattern researchers link to its reported effects across a wide range of situations where the immune system is under strain, including severe infection, cancer treatment, and vaccination in people whose immune response tends to be weaker, such as older adults.

How it is studied

Thymosin alpha 1's evidence includes a large, multicenter randomized trial in patients with severe sepsis, a laboratory study of blood samples from people recovering from COVID-19, and a 2024 narrative review that gathers findings from more than 30 published trials and over 11,000 participants. That scale of trial activity mostly reflects its use outside the United States, where the medicine built on this peptide has been approved and prescribed for decades. The 2024 review was written to argue against a 2023 US regulatory restriction on compounding the peptide, a stated position worth weighing alongside its conclusions.

What studies report

• In a 361-patient randomized trial in adults with severe sepsis, 28-day deaths were lower with thymosin alpha 1 than with standard care alone, 26.0 percent versus 35.0 percent, but the difference narrowly missed the trial's own threshold for statistical significance in its main analysis. [1]
• In that same sepsis trial, a laboratory marker of immune cell function improved significantly more with thymosin alpha 1 than with standard care by day three and day seven. [1]
• In laboratory tests on blood samples from people with lingering symptoms after COVID-19, adding thymosin alpha 1 to the samples improved several measures of immune cell balance, an effect that was largest in samples from people who had needed breathing support during their initial illness. [2]
• A 2024 narrative review of more than 30 clinical trials and over 11,000 patients described thymosin alpha 1 as a well-tolerated immune modulator with a favorable long-term safety record, while also arguing that a US regulatory restriction on the peptide should be reversed. [3]

What is not known

Thymosin alpha 1 is not approved in the United States, so much of its trial evidence comes from other regulatory environments with different standards for trial design and reporting than the ones the FDA requires. The largest single randomized trial behind its reputation, in severe sepsis, did not reach statistical significance on its main survival measure, even though the trend favored the peptide. The 2024 review most often cited for its overall safety and effectiveness record was written explicitly to oppose a US restriction on the peptide and appeared in a journal outside mainstream biomedical indexing, a conflict of purpose that readers should weigh against its favorable conclusions. How its broad immune effects compare directly with narrower, single-target immune therapies has not been resolved by a head-to-head trial.

Reported adverse findings

• Across the reviewed trial record, fewer than 1 in 100 of the more than 11,000 patients studied experienced a serious adverse event, which researchers describe as a favorable safety profile for a compound with such broad immune activity. [3]

Regulatory status

Thymosin alpha 1, marketed under brand names including Zadaxin and Thymalfasin, is approved as a medicine in more than 35 countries. The United States Food and Drug Administration has not cleared it, so it holds no medicine approval there.